Designing appropriate therapy in the treatment of gram-negative bacillary meningitis.
Gram-negative bacillary meningitis is being diagnosed more frequently, and the introduction of newer beta-lactam antibiotics has contributed significantly to successful therapy. These new agents--became of their ease of administration and relative safety--also allow nonspecialists to treat the disease. There are, however, pitfalls in therapy of infections due to this heterogenous group of organisms. Extremely susceptible organisms, such as Escherichia coli and Klebsiella pneumoniae, most often respond to cephalosporin monotherapy, whereas relatively resistant organisms such as Acinetobacter and some Enterobacter may not. In these cases, combination therapy with an aminoglycoside is warranted. Testing the infecting organism for antibiotic susceptibility at the appropriate inoculum and pH may be useful in predicting therapeutic outcome.[1]References
- Designing appropriate therapy in the treatment of gram-negative bacillary meningitis. Corrado, M.L., Gombert, M.E., Cherubin, C.E. JAMA (1982) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg